Role of Interleukin-2 Receptor in Signal Transduction and Gravisensing Threshold of T-Lymphocytes-2 (Leukin-2) - 08.05.15

Overview | Description | Applications | Operations | Results | Publications | Imagery

ISS Science for Everyone

Science Objectives for Everyone
Leukin-2 will study the signal transduction pathway of the activation of T-lymphocytes. This investigation will also determine if loss of Interleukin-2 receptor expression is the cause of inhibition. Microgravity will be used as an inhibitor of activation.
Science Results for Everyone
Information Pending

The following content was provided by Isabelle Walther, Ph.D., and is maintained in a database by the ISS Program Science Office.
Information provided courtesy of the Erasmus Experiment Archive.
Experiment Details


Principal Investigator(s)
Isabelle Walther, Ph.D., Swiss Federal Institute of Technology, Space Biology, Zurich, Switzerland

Augusto Cogoli, Ph.D., Zero-g Tec GmbH, Zurich, Switzerland
Millie Hughes-Fulford, Ph.D., University of California, San Francisco, CA, United States
Proto Pippia, Universiy of Sassari, Sassari, Italy

Swiss Federal Institute of Technology, Space Biology, Zurich, Switzerland

Sponsoring Space Agency
European Space Agency (ESA)

Sponsoring Organization
Information Pending

Research Benefits
Information Pending

ISS Expedition Duration
September 2006 - April 2007

Expeditions Assigned

Previous ISS Missions
A previous Leukin investigation was flown on STS-107 (Columbia) in 2003. This investigation will fly again for ESA on Expedition 14.

^ back to top

Experiment Description

Research Overview

  • Leukin-2 will help investigators understand why single cells are sensitive to microgravity and to study the microgravity effect on the immune system cells.

  • The results of Leukin-2 will enable understanding of the cause of reduced immune function associated with spaceflight so crew members stationed on the Moon or on a Mars mission will remain healthy.

The International Space Station provides a modern platform to study physiology and molecular changes in space. In addition, understanding these physiological changes provides knowledge that we can apply to common diseases found in the general population. The results also help us to understand microgravity-induced immunosuppression.

Early NASA studies demonstrated that the lymphocytes (white blood cells) had a decreased response to mitogen stimulation of growth. In the late 60's returning Apollo astronauts were found to have reduced immune function after spaceflight, taking approximately 7 days to recover normal function. Astronauts exposed to microgravity did not respond to mitogen, a protein that encourages cell division, while cells belonging to non-flown astronaut backups had normal response.

The aim of Leukin-2 is to study the signals which cause the activation of T-lymphocytes, white blood cells that play a central role in cell-mediated immunity. The focus is on the role of Interleukin-2 (IL-2), a hormone that stimulates the growth of T-lymphocytes and plays an instrumental role in the body's response to pathogens (bacteria, viruses, fungi, etc.) and in the determination of its genetic expression (process by which a gene's DNA sequence is converted into the structures and functions of a cell).

^ back to top


Space Applications
Leukin-2 may help scientists to better understand the depression of the immune system which occurs during spaceflight and, therefore, to devise more adequate preventive or corrective measures for crew members during long duration missions.

Earth Applications
Determining the factors which cause IL-2 suppression can help scientists on Earth better treat immunosuppressed patients.

^ back to top


Operational Requirements
Cells will be prepared at the launch site just prior to launch from fresh human blood. The purified T-lymphocytes will be loaded into experiment containers just prior to launch. Following arrival on ISS, fixative will be added to a specified group of the cells. Fixative will be added to another group of cells 30 minutes following arrival on ISS and to a third group 4 hours after arrival on ISS.

Operational Protocols
The T-lymphocytes will be purified and sealed in experiment containers shortly before launch. Once on orbit an astronaut will inject an activator. After intervals of 0 minutes, 30 minutes and 4 hours the cultures will be fixed, by injection of a preservation solution, frozen and returned to the investigators for analysis.

^ back to top

Results/More Information

Information Pending

^ back to top

Results Publications

    Chang TT, Walther I, Li C, Boonyaratanakornkit JB, Galleri G, Meloni MA, Pippia P, Cogoli A, Hughes-Fulford M.  The Rel/NF-κB pathway and transcription of immediate early genes in T cell activation are inhibited by microgravity. Journal of Leukocyte Biology. 2012; 92(6): 1133-1145. DOI: 10.1189/jlb.0312157. PMID: 22750545.

^ back to top

Ground Based Results Publications

^ back to top

ISS Patents

^ back to top

Related Publications

    Sonnenfeld G.  Editorial: Space flight modifies T cell activation--role of microgravity. Journal of Leukocyte Biology. 2012 December 1; 92(6): 1125-1126. DOI: 10.1189/jlb.0612314.

^ back to top

Related Websites
The information provided is courtesy of the ESA Astrolab Mission web page.
The Lab of Cell Growth - University of California Medical School, San Fancisco, CA
Space Biology Group

^ back to top